TNDM

AI Memo

Tandem Diabetes Care

As of 2026-09-26/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Mobi tubeless regulatory decision and launch • 2026-12-31

Base target: $18 / p=50% prob

Biggest risk

U.S. pump shipments grew only modestly year over year, Tandem remained GAAP loss-making in Q2, and Mobi tubeless still requires regulatory clearance. An observed post-results revision cut RBC Capital's target to $26 from $30 while retaining Outperform; this is one revision, not evidence of a broad analyst trend. [#SEC-8K-2026-08-06] RBC revision reported by The Fly

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Q2 sales rose 6% to $254.6 million, gross margin reached 57%, and adjusted EBITDA turned positive at $6.4 million. Tandem reaffirmed 2026 sales guidance of $1.065 billion–$1.085 billion and adjusted EBITDA margin guidance of 5%–6%. Mobi tubeless clearance and sustained pharmacy-channel adoption could improve the growth outlook. [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-26

Base target

$18

p=50%

Bull target

$25

p=25%

Bear target

$10

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

U.S.
pump and pharmacy-channel traction
International expansion and sustained operating leverage

BearKey bullets

Competition from established tubeless and integrated insulin-delivery systems could constrain adoption.
Insulet release MiniMed release
FDA review or launch delays for Mobi tubeless could defer the product catalyst.

WatchKey bullets

Mobi tubeless regulatory decision and launch

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $18 (p=50%)

Target spread vs base: +39% / -44%

Scenario probabilities

Bull Target: $25 (p=25%)Base Target: $18 (p=50%)Bear Target: $10 (p=25%)

Commentary

The $15.72 September 25 anchor is about 6.8% below the prior baseline's $16.87 price, despite constructive Q2 operating evidence. The packet does not establish the cause of the intervening decline. One target cut is confirmed, but comprehensive post-print estimate revisions and a reliable explanation of the price reaction are unavailable. The positive deterministic prior supports an upside-skewed watchlist view, not a high-conviction upgrade. Sentiment metric zeros denote unavailable measurements, not neutral readings. The August Form 4 disposition was tax withholding, not evidence of discretionary selling or operating weakness. [#SEC-FORM4-2026-08-18]

As of 2026-09-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

U.S. pump and pharmacy-channel traction
International expansion and sustained operating leverage

Scenarios

Bull Target (Scenario probability)

$25 / p=25% prob

Base Target (Scenario probability)

$18 / p=50% prob

Bear Target (Scenario probability)

$10 / p=25% prob

Analysis 2026-09-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Mobi tubeless regulatory decision and launch
Tandem reported submitting a 510(k) for Mobi tubeless capability in Q2. Clearance and commercialization could broaden its pump offering; the decision date and launch timing remain uncertain. The date shown is a monitoring window, not an announced deadline. [#SEC-8K-2026-08-06] [#8-K-2026-08-06]
Prob 55.00% • Move 18.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

U.S. pump and pharmacy-channel traction
2026-11-30
Q2 U.S. pump shipments exceeded 22,000 versus approximately 21,000 a year earlier, while the pay-as-you-go model accounted for 10% of U.S. sales. Subsequent shipment and channel-mix disclosures will test whether adoption accelerates without eroding margins. The date is an estimated review window. [#SEC-8K-2026-08-06]
Prob 55% • Move 11% • Priced-in 40%

Long-term Catalysts

Months to a year

International expansion and sustained operating leverage
2027-06-30
Q2 international pump shipments were approximately 11,000 versus 9,000 a year earlier, Tandem began the international Mobi rollout, and gross margin reached 57%. Sustained growth and margin gains would strengthen the profitability case, but one quarter does not establish a durable trend. [#SEC-8K-2026-08-06]
Prob 55% • Move 20% • Priced-in 30%

Risks

Competition from established tubeless and integrated insulin-delivery systems could constrain adoption. Insulet release MiniMed release
FDA review or launch delays for Mobi tubeless could defer the product catalyst. [#SEC-8K-2026-08-06]
Modest U.S. pump-shipment growth may fall short of what is needed to sustain the reaffirmed sales outlook. [#SEC-8K-2026-08-06]
Pharmacy-channel mix and international rollout costs could make recent margin improvement difficult to sustain; Tandem still reported a Q2 operating and net loss. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
BBNX	Beta Bionics' iLet is another direct automated-insulin-delivery comparator, though its product portfolio and commercialization stage differ from Tandem's. Beta Bionics release
PODD	Insulet's Omnipod 5 is a direct tubeless automated-insulin-delivery competitor, making it relevant to Mobi positioning; scale and product economics still differ. Insulet release
MMED	MiniMed is a direct insulin-pump competitor and has traded separately since its 2026 IPO. Its integrated device mix limits simple valuation comparisons. MiniMed company release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-26

Loading AI feed…

Symbol

Summary

BBNX

Beta Bionics' iLet is another direct automated-insulin-delivery comparator, though its product portfolio and commercialization stage differ from Tandem's. Beta Bionics release

PODD

Insulet's Omnipod 5 is a direct tubeless automated-insulin-delivery competitor, making it relevant to Mobi positioning; scale and product economics still differ. Insulet release

MMED

MiniMed is a direct insulin-pump competitor and has traded separately since its 2026 IPO. Its integrated device mix limits simple valuation comparisons. MiniMed company release